Home Tags Triple negative breast cancer

Tag: triple negative breast cancer

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

Indatuximab Ravtansine Shows Good Tolerability and Signs of Efficacy in Phase...

Results for Phase I/IIa study confirms that indatuximab ravtansine, also known as BT-062, an antibody-drug conjugate being developed by Biotets, offers good tolerability and...

Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...

Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...

Sacituzumab Govitecan Receives Breakthrough Therapy Designation for Triple-negative Breast Cancer

The investigational antibody-drug conjugate, sacituzumab govitecan, also know as IMMU-132 (Immunomedics), has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA)...

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...

FEATURED RESOURCES